LTRN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process...

Stats
Today's Volume	123 511
Average Volume	320 219
Market Cap	58.65M
EPS	$0 ( 2024-03-18 )
Next earnings date	( $-0.400 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.71
ATR14	$0.0380 (0.70%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-27	Fletcher Aaron G.l.	Sell	34 731	Common Stock
2024-02-28	Fletcher Aaron G.l.	Sell	51 608	Common Stock
2024-02-29	Fletcher Aaron G.l.	Sell	13 686	Common Stock
2024-02-27	Fletcher Aaron G.l.	Sell	10 620	Common Stock
2024-02-28	Fletcher Aaron G.l.	Sell	15 780	Common Stock

INSIDER POWER
-62.88
Last 98 transactions
Buy: 4 152 509 \| Sell: 1 662 260

Volume Correlation

Long: -0.10 (neutral)

Short: 0.80 (moderate)

Signal:(47.762) Neutral

Lantern Pharma Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lantern Pharma Inc. Correlation - Currency/Commodity

-0.08
( neutral )

0.59
( weak )

0.00
( neutral )

0.02
( neutral )

0.07
( neutral )

0.73
( moderate )

Lantern Pharma Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-174 843 (0.00 %)
EPS:	$-1.470

FY	2023
Revenue:	$0
Gross Profit:	$-174 843 (0.00 %)
EPS:	$-1.470

FY	2022
Revenue:	$0
Gross Profit:	$-154 681 (0.00 %)
EPS:	$-1.300

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.105

Financial Reports:

No articles found.

Lantern Pharma Inc.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.